Search Result

Results for "

Aromatase Inhibitors

" in MCE Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (1) Aryl Hydrocarbon Receptor (1) Autophagy (2) Bacterial (1) Cytochrome P450 (29) Drug Metabolite (3) Estrogen Receptor/ERR (4) Fungal (2) Isotope-Labeled Compounds (5) Monoamine Oxidase (1) NO Synthase (1) Parasite (3) Phosphodiesterase (PDE) (1) PPAR (1) Progesterone Receptor (1)
By Research Areas:	Cancer (24) Cardiovascular Disease (2) Endocrinology (13) Infection (3) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-14274

Anastrozole 2 Publications Verification ZD1033	Cytochrome P450	Cancer
Anastrozole is a potent, highly selective *aromatase* inhibitor, which inhibits human placental aromatase with an IC₅₀ of 15 nM.

HY-150775

*Nonsteroidal aromatase* inhibitor 1**	Cytochrome P450	Cancer
Nonsteroidal aromatase inhibitor 1 (Compound 13h) is a nonsteroidal *aromatase* (CYP19A1) inhibitor (IC₅₀=0.09 nM). Nonsteroidal aromatase inhibitor 1 has potential for breast cancer research.

HY-148430

Aromatase-IN-2

Cytochrome P450 Cancer

Aromatase-IN-2 is a potent aromatase inhibitor with an IC₅₀ value of 1.5 µM.

Aromatase-IN-2	Cytochrome P450	Cancer
Aromatase-IN-2 is a potent *aromatase* inhibitor with an IC₅₀ value of 1.5 µM.

HY-144824

Monoamine oxidase/Aromatase-IN-1	Cytochrome P450 Monoamine Oxidase	Cancer Neurological Disease
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and *aromatase* dual inhibitor with IC₅₀s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer.

HY-14274S

Anastrozole-d12 ZD1033-d₁₂	Cytochrome P450 Isotope-Labeled Compounds	Cancer
Anastrozole-d₁₂ is the deuterium labeled Anastrozole. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM[1][2].

HY-U00176

Org30958

Cytochrome P450 Metabolic Disease

Org30958 is a potent aromatase inhibitor in vivo.

Org30958	Cytochrome P450	Metabolic Disease
Org30958 is a potent *aromatase* inhibitor in vivo.

HY-N5012

Eurycomanone Pasakbumin A	Phosphodiesterase (PDE)	Endocrinology
Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.

HY-13632

Exemestane 2 Publications Verification FCE 24304; EXE	Cytochrome P450	Cancer Endocrinology
Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal *aromatase* inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.

HY-14247

Fadrozole hydrochloride 1 Publications Verification CGS 16949A; (Rac)-FAD286 hydrochloride	Cytochrome P450	Cancer Endocrinology
Fadrozole hydrochloride (CGS 16949A) is a potent, selective and nonsteroidal inhibitor of *aromatase* with an IC₅₀ of 6.4 nM.

HY-14247A

Fadrozole 1 Publications Verification CGS 16949A free base; (Rac)-FAD286	Cytochrome P450	Cancer
Fadrozole (CGS 16949A free base) is a potent, selective and nonsteroidal inhibitor of *aromatase* with an IC₅₀ of 6.4 nM.

HY-13632S

Exemestane-d2 FCE 24304-d₂; EXE-d₂	Cytochrome P450 Isotope-Labeled Compounds	Cancer Endocrinology
Exemestane-d₂ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S2

Exemestane-d3 FCE 24304-d₃; EXE-d₃	Cytochrome P450 Isotope-Labeled Compounds	Cancer Endocrinology
Exemestane-d₃ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S1

Exemestane-13C3	Cytochrome P450 Isotope-Labeled Compounds	Cancer Endocrinology
Exemestane-¹³C₃ is the ¹³C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-W392925

(R)-(+)-Aminoglutethimide d-Aminoglutethimide	Cytochrome P450	Cancer
(R)-(+)-Aminoglutethimide is a potent and orally active *aromatase* inhibitor. (R)-(+)-Aminoglutethimide has the potential for the research of breast cancer.

HY-13632R

Exemestane (Standard) FCE 24304(Standard); EXE (Standard)	Cytochrome P450	Cancer Endocrinology
Exemestane (Standard) is the analytical standard of Exemestane. This product is intended for research and analytical applications. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal *aromatase* inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.

HY-146688

SYN20028567

Cytochrome P450 Cancer

SYN20028567 is an aromatase (CYP19) inhibitor with an IC₅₀ of 9.4 nM. SYN20028567 can be used for breast cancer research.

SYN20028567	Cytochrome P450	Cancer
SYN20028567 is an aromatase (CYP19) inhibitor with an IC₅₀ of 9.4 nM. SYN20028567 can be used for breast cancer research.

HY-125833

Alpha-Naphthoflavone 4 Publications Verification	Cytochrome P450	Cancer
Alpha-Naphthoflavone is a flavonoid, acts as a potent and competitive *aromatase* inhibitor with an IC₅₀ and a K_i of 0.5 and 0.2 μM, respectively.

HY-105184

YM511	Cytochrome P450	Endocrinology
YM511 is a highly specific non-steroidal *aromatase* inhibitor. YM511 inhibits aromatase activities in microsomes from rat ovary and human placenta competitively (IC50s of 0.4 and 0.12 nM, respectively). YM511 slightly inhibits production of other steroid hormones. YM511 has the potential for suppressing estrogen-dependent action research without affecting serum levels of other steroid hormones.

HY-N0292

Oleuropein 1 Publications Verification	Cytochrome P450 PPAR Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity. Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits *aromatase*.

HY-19599

Vorozole (+)-Vorozole; R83842	Cytochrome P450	Cancer
Vorozole is a potent and selective, orally active non-steroidal *aromatase* inhibitor. Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer.

HY-18719B

Endoxifen hydrochloride	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study.

HY-18719E

Endoxifen	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study.

HY-14248

Letrozole Maximum Cited Publications 14 Publications Verification CGS 20267	Cytochrome P450 Autophagy	Cancer
Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of *aromatase, with an IC₅₀* of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.

HY-W087008

7-Hydroxyflavanone	Cytochrome P450	Cancer Endocrinology
7-Hydroxyflavanone is a potent inhibitor of *aromatase* (CYP19) activity with the IC₅₀ of 65 μM. 7-Hydroxyflavanone exerts various biological effects, including anticarcinogenic, antioxidant and (anti-)estrogenic effects, and modula

HY-113986

Dexfadrostat (R)-Fadrozole; (R)-CGS 16949A free base; FAD286	Others	Cardiovascular Disease
Dexfadrostat ((R)-Fadrozole) is a potent nonsteroidal inhibitor. Dexfadrostat also inhibits human placental aromatase (pIC₅₀ = 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats..

HY-18719ES

Endoxifen-d5	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

HY-N3246

Morachalcone A	NO Synthase	Inflammation/Immunology
Morachalcone A is a naturally-occurring aromatase inhibitor (IC₅₀=4.6 mM). Morachalcone A is also a plants metabolite with potential anti-inflammatory and anticancer activity. Morachalcone A inhibits Lipopolysaccharide (HY-D1056)-induced nitric oxide production.

HY-136063

Mefentrifluconazole	Fungal Cytochrome P450	Infection
Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (K_d= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC₅₀=0.92 μM).

HY-14247B

Fadrozole hydrochloride hemihydrate CGS 16949A hemihydrate; (Rac)-FAD286 hydrochloride hemihydrate	Cytochrome P450	Cancer Endocrinology
Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal *aromatase* inhibitor, with an IC₅₀ of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC₅₀ values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer.

HY-B0845

Prochloraz BTS 40542	Fungal Estrogen Receptor/ERR Androgen Receptor Aryl Hydrocarbon Receptor	Infection Endocrinology
Prochloraz is an imidazole antifungal. Prochloraz is as an estrogen receptor (ER) and androgen receptor (AR) antagonist and an *aromatase* inhibitor with IC₅₀ values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the aryl hydrocarbon receptor (AhR) having an EC₅₀ of 1 μM.

HY-14248S

Letrozole-d4	Cytochrome P450 Isotope-Labeled Compounds Autophagy	Cancer
Letrozole-d₄ (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer[1][2][3].

HY-152250

Antibacterial agent 132	Cytochrome P450 Bacterial	Infection
Antibacterial agent 132 has anticandidal effects against C. parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) with MIC₉₀ values of <0.06 μg/mL and 62.50 μg/mL, respectively. Antibacterial agent 132 inhibits aromatase enzyme with an IC₅₀ of 0.047μM.

HY-B0084

Dienogest 1 Publications Verification STS 557	Progesterone Receptor	Endocrinology
Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE₂ synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia.

HY-136092

Androsta-1,4,6-triene-3,17-dione	Cytochrome P450	Endocrinology Neurological Disease
Androsta-1,4,6-triene-3,17-dione is a lipophilic and specific *aromatase* inhibitor with a K_i of 0.18 μM. Androsta-1,4,6-triene-3,17-dione inhibits estrogen biosynthesis and shows antifertility effects. Androsta-1,4,6-triene-3,17-dione induces impairment of spatial memory.

Cat. No.	Product Name	Target	Category

HY-N5012

Eurycomanone Pasakbumin A	Phosphodiesterase (PDE)	Terpenoids Diterpenoids Classification of Application Fields Disease Research Fields Endocrinology Source classification Plants other families
Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.

HY-125833

Alpha-Naphthoflavone 4 Publications Verification	Cytochrome P450	Flavones Flavonoids Compositae Indigofera heterantha Wall. ex Brand. Plants Source classification Disease Research Fields Cancer
Alpha-Naphthoflavone is a flavonoid, acts as a potent and competitive *aromatase* inhibitor with an IC₅₀ and a K_i of 0.5 and 0.2 μM, respectively.

HY-N0292

Oleuropein 1 Publications Verification	Cytochrome P450 PPAR Apoptosis	Iridoids Terpenoids Phenols Polyphenols Structural Classification Canarium album (Lour.) Rauesch. Burseraceae Plants Source classification Inflammation/Immunology Disease Research Fields Cancer Anti-aging Classification of Application Fields Cardiovascular Disease
Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity. Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits *aromatase*.

HY-14248

Letrozole Maximum Cited Publications 14 Publications Verification CGS 20267	Cytochrome P450 Autophagy	Alkaloids Compositae Plants Source classification Tephrosia purpurea (L.) Pers. Disease Research Fields Cancer Classification of Application Fields
Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of *aromatase, with an IC₅₀* of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.

HY-W087008

7-Hydroxyflavanone	Cytochrome P450	Monophenols Phenols Papilionaceae Dalbergia cochinchinensis Plants Source classification Disease Research Fields Cancer Endocrinology
7-Hydroxyflavanone is a potent inhibitor of *aromatase* (CYP19) activity with the IC₅₀ of 65 μM. 7-Hydroxyflavanone exerts various biological effects, including anticarcinogenic, antioxidant and (anti-)estrogenic effects, and modula

HY-N3246

Morachalcone A	NO Synthase	Structural Classification Phenols Polyphenols Morus alba Linn. Plants Source classification Moraceae
Morachalcone A is a naturally-occurring aromatase inhibitor (IC₅₀=4.6 mM). Morachalcone A is also a plants metabolite with potential anti-inflammatory and anticancer activity. Morachalcone A inhibits Lipopolysaccharide (HY-D1056)-induced nitric oxide production.

Cat. No.	Product Name

HY-14274S

Anastrozole-d12
Anastrozole-d₁₂ is the deuterium labeled Anastrozole. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM[1][2].

HY-13632S

Exemestane-d2
Exemestane-d₂ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S2

Exemestane-d3
Exemestane-d₃ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S1

Exemestane-13C3
Exemestane-¹³C₃ is the ¹³C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-18719ES

Endoxifen-d5
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

HY-14248S

Letrozole-d4
Letrozole-d₄ (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer[1][2][3].

Aromatase Inhibitors

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products